AC Immune SA (ACIU)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.37
- As of
Kresmion compiles this page from ACIU's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AC Immune SA (ACIU): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-02.
See the full ACIU dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ACIU on one page. Preview it with sample data, then open it live with a free account.
Preview the ACIU dossierActive events for ACIU
- mediumEarnings above estimates
Q2-2026: Beat consensus by 117.6%, EPS $0.02 vs $-0.1136 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +201% to ACIU (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1721% to ACIU (2026Q2)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +163% to ACIU (2026Q2)
- high13F: large increase
Point72 Asset Management, L.P. added +951% to ACIU (2026Q1)
FREE, NO ACCOUNT
Every event on ACIU, as it fires
You are seeing 5 of 9 events recorded on ACIU since 2026-06-21.
The five above landed across 3 days. The other 4 were recorded on 1 other days. 5 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ACIU (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP H00263105 · 2026Q2 | $2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP H00263105 · 2026Q2 | $1.8M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP H00263105 · 2026Q2 | $494K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP H00263105 · 2026Q2 | $245K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ACIU
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
ACIU against its peers
ACIU's operating margin of -1940.1% ranks in the 27th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ACIU | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 3.6M CHF | n/a | n/a | 0 |
| Revenue YoY | -86.9% | n/a | n/a | 2 |
| Operating margin | -1940.1% | -296.0% | 27 | 12 |
| Net margin | -1971.6% | -301.7% | 32 | 13 |
| Return on equity | -157.0% | -40.5% | 11 | 21 |
Peers (23): IMRX, VNDA, LRMR, GLSI, BCYC, CABA, PALI, OCGN, RCKT, QTTB, LYEL, ABEO, IFRX, LXEO, FATE, LCTX, SLGL, NWBO, SABS, IKT, IPSC, KROS, ZNTL. Left out: VCRE (no annual filing), CUVL (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ACIU: 20-F), reported in CHF. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ACIU on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ACIU for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.